Generic Name and Formulations:
Levonorgestrel 0.1mg, ethinyl estradiol 20mcg (21 tabs); inert (7 tabs).
Indications for LUTERA:
1 tab daily for 28 days; repeat.
Thrombophlebitis or thromboembolic disorders. Cerebral vascular or coronary artery disease. Breast or other estrogen-dependent neoplasms. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy or jaundice with prior OC use. Hepatic adenoma or carcinoma. Pregnancy (Cat.X).
Smokers over 35yrs of age: not recommended. Uncontrolled hypertension. Hypertriglyceridemia. Discontinue if jaundice, visual disturbances, migraine or other severe headaches occur. Do regular complete physical exams. May need barrier contraception with Sunday starts or postpartum use (see literature). Nursing mothers: not recommended.
Antagonized by hepatic enzyme inducing drugs (eg, rifampin, griseofulvin, St. John's wort), possibly others. May affect measurement of sex hormone-binding globulin levels.
Progestin + estrogen.
Hypertension, nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, mastodynia, headache, intolerance to contact lenses. Increased risk of gallbladder disease, thromboembolic disorders.
Sign Up for Free e-newsletters
- 2016 Recommended Immunization Schedule for Adults: What's Changed?
- 2016 Childhood and Adolescent Immunization Schedule Released
- Spiriva Respimat Gains Indication and New Dosage Strength
- First Sexually-Transmitted Zika Virus Case Confirmed in Texas
- To Rx or Not to Rx: Interventions to Improve Antibiotic Prescribing for Uncomplicated Acute RTI
- New Study Proposes Strategies for Pain Control After Total Knee Replacement
- CDC: Novel Lyme Disease Pathogen Discovered
- FDA to Review Rexulti as Maintenance Therapy for Schizophrenia
- Case Illustrates Impact of Dabigatran-Phenytoin Interaction
- Real-World Data on Retreating HCV Patients With NS5A Inhibitor Failure